ASH 2023 | XPORT-MF-034: selinexor plus ruxolitinib in JAK-inhibitor naïve myelofibrosis
Keri Maher
• 9 Dec 2023
Keri Maher, DO, VCU Health, Richmond, VA, briefly discusses the Phase I portion of the XPORT-MF-034 (NCT04562389) study – a global, Phase III, randomized, double-blind study to evaluate the safety and efficacy of selinexor in combination with ruxolitinib in patients with JAK-inhibitor naïve myelofibrosis (MF). The study is currently open for enrollment, and 306 patients have been enrolled since June 2023. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Sobi (Doptelet)
Board of Directors/Advisory committee: Bristol Myers Squibb
